title: [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
authors.affiliation: Unidad de Oncología Hepática (BCLC), Servicio de Hepatología, Hospital Clínic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), IDIBAPS, Universidad de Barcelona, Barcelona, España.
authors.forename: María
authors.initials: M
authors.lastname: Reig
authors.forename: Ana
authors.initials: A
authors.lastname: Matilla
authors.forename: Javier
authors.initials: J
authors.lastname: Bustamante
authors.forename: Luís
authors.initials: L
authors.lastname: Castells
authors.forename: Manuel
authors.initials: M
authors.lastname: de La Mata
authors.forename: Manuel
authors.initials: M
authors.lastname: Delgado
authors.forename: José María
authors.initials: JM
authors.lastname: Moreno
authors.forename: Alejandro
authors.initials: A
authors.lastname: Forner
authors.forename: María
authors.initials: M
authors.lastname: Varela
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology / Q000451:nursing; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology; D004347:Drug Interactions; D016903:Drug Monitoring; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000628:therapy; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology / Q000451:nursing; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009536:Niacinamide / Q000031:analogs & derivatives; D018579:Patient Selection; D010671:Phenylurea Compounds; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011859:Radiography; D000077157:Sorafenib; D013030:Spain; D048490:raf Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D009363:Neoplasm Proteins; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D048490:raf Kinases